Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney disease, ...

Form and Administration: Frequency: Strengths and Dosing Schedules: Rybelsus tablets are available in 3 milligrams (mg), 7 mg, and 14 mg strengths. The typical starting dosage is 3 mg once daily ...

Another effect that Rybelsus has is that it can promote weight loss via appetite control. Although not approved for weight loss, this semaglutide tablet is often prescribed off label by healthcare ...

Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial 1.

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly ...